Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun Pharma introduces...

    Sun Pharma introduces anti-cancer product in Europe

    Written by savita thakur thakur Published On 2016-07-13T14:03:49+05:30  |  Updated On 13 July 2016 2:03 PM IST
    Sun Pharma introduces anti-cancer product in Europe

    New Delhi : Sun Pharmaceutical Industries announced rollout of Gemcitabine InfuSMART, used in treatment of cancer, in Europe.


    "As part of its business strategy to build a meaningful and differentiating presence in global oncology therapy market, Sun Pharma announced rollout of Gemcitabine InfuSMART in Europe. InfuSMART is a technology in which oncology products are developed in a ready to administer (RTA) bag," the company said in a BSE filing.


    "Until now, compounding of oncology products was done at compounding centres or compounded in hospital pharmacies, an extra step before the medicine can be administered to patients.


    Over the next few months, Sun Pharma will launch Gemcitabine InfuSMART across the Netherlands, the UK, Spain, Germany, Italy and France.


    Sun Pharma Business Head Western Europe & ANZ Hellen de Kloet said: "Sun Pharma's Gemcitabine InfuSMART ready-to-administer infusion products provide the combined advantage of long stable compounded medicine along with safety. Traditionally, such medicines are compounded at hospitals (in-house) or outsourced to compounding pharmacies, making it a time consuming and potentially hazardous process."


    Kloet added: "Launch of InfuSMART will help us remain a meaningful player in the global oncology therapy market by offering differentiating cancer treatment solutions. We believe there are opportunities for us to expand our portfolio of ready-to-administer products across multiple therapies where time and safety are an important element of treatment."


    Sun Pharma has received regulatory approval to produce Gemcitabine InfuSMART in eight key SKUs (stock keeping units).


    "More InfuSMART oncology products are currently in Sun Pharma's pipeline to be rolled out in future," it added.


    With the rollout of Gemcitabine InfuSMART, Sun Pharma said it has become "the world's first pharmaceutical company to manufacture and launch a licensed RTA oncology product".

    anti cancercancercancer treatmentGemcitabine InfuSMARTHellen de Kloethospital pharmaciesready to administerrolloutRTASKUsstock keeping unitsSun Pharma
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok